scholarly journals Revisiting olfactory receptors as putative drivers of cancer

2017 ◽  
Vol 2 ◽  
pp. 9 ◽  
Author(s):  
Marco Ranzani ◽  
Vivek Iyer ◽  
Ximena Ibarra-Soria ◽  
Martin Del Castillo Velasco-Herrera ◽  
Mathew Garnett ◽  
...  
Keyword(s):  
Signal Transduction ◽  
Cell Lines ◽  
Cancer Cell ◽  
Olfactory Receptor ◽  
Receptor Gene ◽  
Signal Transduction Pathway ◽  
Olfactory Receptors ◽  
Cancer Cell Lines ◽  
Specific Manner ◽  
Olfactory Receptor Genes

Background: Olfactory receptors (ORs) recognize odorant molecules and activate a signal transduction pathway that ultimately leads to the perception of smell. This process also modulates the apoptotic cycle of olfactory sensory neurons in an olfactory receptor-specific manner. Recent reports indicate that some olfactory receptors are expressed in tissues other than the olfactory epithelium suggesting that they may have pleiotropic roles. Methods: We investigated the expression of 301 olfactory receptor genes in a comprehensive panel of 968 cancer cell lines. Results: Forty-nine per cent of cell lines show expression of at least one olfactory receptor gene. Some receptors display a broad pattern of expression across tumour types, while others were expressed in cell lines from a particular tissue. Additionally, most of the cancer cell lines expressing olfactory receptors express the effectors necessary for OR-mediated signal transduction. Remarkably, among cancer cell lines, OR2C3 is exclusively expressed in melanoma lines. We also confirmed the expression of OR2C3 in human melanomas, but not in normal melanocytes. Conclusions: The pattern of OR2C3 expression is suggestive of a functional role in the development and/or progression of melanoma. Some olfactory receptors may contribute to tumorigenesis.

QS283. Effect of Activin ond Smad 3 Signal Transduction on Breast Cancer Cell Lines

2008 ◽  
Vol 144 (2) ◽  
pp. 379 ◽  
Author(s):  
Supurna Ghosh ◽  
Kelly Fitzgerald ◽  
Kerstyn Syc Bryce ◽  
Jacqueline S. Jeruss
Keyword(s):  
Breast Cancer ◽  
Signal Transduction ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Smad 3

scholarly journals Andrographolide as a therapeutic agent against breast and ovarian cancers

2019 ◽  
Vol 14 (1) ◽  
pp. 462-469 ◽  
Author(s):  
Swarna Latha Beesetti ◽  
Mavuluri Jayadev ◽  
Gnana Veera Subhashini ◽  
Lamjed Mansour ◽  
Saleh Alwasel ◽  
...  
Keyword(s):  
Cell Lines ◽  
Cancer Cell ◽  
Signal Transduction Pathway ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Caspase 8 ◽  
Breast Cancers ◽  
Ecm Degradation ◽  
Matrix Metallopeptidase ◽  
Light Chain Enhancer

AbstractAndrographolide (ANDR), isolated from Andrographis paniculata, is a medicinal compound effective against infections, inflammatory disorders, and various cancers. In the present study, the effects of ANDR on NFkB (nuclear factor kappa-light-chain-enhancer of activated B cells) activation, caspase-8-mediated apoptosis and pyroptosis, and extra cellular matrix (ECM) degradation were analyzed in A431, MDA-MB231, and SKOV-3 cell lines. Results showed that ANDR inhibited the growth and proliferation of cancer cell lines by inhibiting NFkB signaling. A significant decrease in phospho-p65 level was observed upon increasing ANDR concentration in epidermoid carcinoma and breast cancer cell lines, A431 and MDA-MB231, respectively. Accordingly, upon ANDR treatment, the expression of caspase-8 was increased, whereas no significant induction of caspase-1 expression was observed. Moreover, we observed a significant increase in the expression of tissue inhibitor of metallopeptidase-1 (TIMP1) upon increasing ANDR concentration. Such induction of TIMP1 inhibited the activity of matrix metallopeptidase-7 (MMP-7), thus preventing the degradation of ECM. Therefore, as ANDR shows cytotoxicity towards cancer cells via the NFkB signal transduction pathway without inducing pyroptosis and blocks breast and ovarian cancer invasion by inhibiting MMP-7 expression through TIMP1 up-regulation, it has the potential to be developed as a drug targeting ovarian and breast cancers.

scholarly journals A high-throughput drug combination screen of targeted small molecule inhibitors in cancer cell lines

2019 ◽  
Vol 6 (1) ◽  
Author(s):  
Åsmund Flobak ◽  
Barbara Niederdorfer ◽  
Vu To Nakstad ◽  
Liv Thommesen ◽  
Geir Klinkenberg ◽  
...  
Keyword(s):  
Signal Transduction ◽  
Cell Viability ◽  
Cell Lines ◽  
Cancer Cell ◽  
Drug Combination ◽  
Cancer Cell Lines ◽  
Drug Combinations ◽  
Clinical Investigations ◽  
Transduction Mechanisms ◽  
Targeting Signal

Abstract While there is a high interest in drug combinations in cancer therapy, openly accessible datasets for drug combination responses are sparse. Here we present a dataset comprising 171 pairwise combinations of 19 individual drugs targeting signal transduction mechanisms across eight cancer cell lines, where the effect of each drug and drug combination is reported as cell viability assessed by metabolic activity. Drugs are chosen by their capacity to specifically interfere with well-known signal transduction mechanisms. Signalling processes targeted by the drugs include PI3K/AKT, NFkB, JAK/STAT, CTNNB1/TCF, and MAPK pathways. Drug combinations are classified as synergistic based on the Bliss independence synergy metrics. The data identifies combinations that synergistically reduce cancer cell viability and that can be of interest for further pre-clinical investigations.

Sign in / Sign up

Export Citation Format

Share Document